Some aspects of application of the combination of formoterol and budesonide: what is changed?
The use of a combination of the inhaled glucocorticosteroid budesonide and beta2-selective long-acting adrenergic agonist formoterol is recommended for both bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD), however, indications for their use have changed significantly over the...
Main Authors: | A. A. Vizel, I. Yu. Vizel |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5428 |
Similar Items
-
Effectiveness and Patient Satisfaction with Budesonide/Formoterol Easyhaler® Among Patients with Asthma or COPD Switching from Previous Treatment: a Real-World Study of Patient-Reported Outcomes
by: Gabriella Gálffy, et al.
Published: (2019-07-01) -
Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
by: Tang B, et al.
Published: (2019-04-01) -
Adherence and quality of life assessment in patients with asthma treatment with budesonide/formoterol via the Elpenhaler device: the COMPLETE study
by: Konstantinos P. Exarchos, et al.
Published: (2022-06-01) -
Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
by: Nan Shang, et al.
Published: (2024-12-01) -
Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients
by: Hyun-moon Back, et al.
Published: (2020-04-01)